Edition:
United Kingdom

Strongbridge Biopharma plc (SBBP.OQ)

SBBP.OQ on NASDAQ Stock Exchange Global Select Market

2.53USD
16 Aug 2019
Change (% chg)

-- (--)
Prev Close
$2.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
71,877
52-wk High
$6.52
52-wk Low
$2.40

Latest Key Developments (Source: Significant Developments)

Strongbridge Biopharma Announces Key Leadership Appointments To Support Next Stage Of Growth
Tuesday, 13 Aug 2019 

Aug 13 (Reuters) - Strongbridge Biopharma plc ::STRONGBRIDGE BIOPHARMA ANNOUNCES KEY LEADERSHIP APPOINTMENTS TO SUPPORT NEXT STAGE OF GROWTH.STRONGBRIDGE BIOPHARMA PLC - ROBERT LUTZ PROMOTED TO CHIEF FINANCIAL OFFICER.STRONGBRIDGE BIOPHARMA PLC - DAVID GILL APPOINTED TO BOARD OF DIRECTORS.STRONGBRIDGE BIOPHARMA PLC - RICHARD S. KOLLENDER APPOINTED TO CHIEF OPERATING OFFICER.STRONGBRIDGE BIOPHARMA PLC - BRIAN DAVIS, CURRENT CHIEF FINANCIAL OFFICER, IS LEAVING COMPANY.STRONGBRIDGE BIOPHARMA PLC - ALL MANAGEMENT AND BOARD CHANGES WILL BECOME EFFECTIVE ON SEPTEMBER 3, 2019.  Full Article

Strongbridge Biopharma Reports Second Quarter 2019 Revenue Of $6.1 Mln
Wednesday, 31 Jul 2019 

July 31 (Reuters) - Strongbridge Biopharma plc ::REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 NON-GAAP LOSS PER SHARE $0.24.Q2 GAAP LOSS PER SHARE $0.15.Q2 EARNINGS PER SHARE ESTIMATE $-0.34 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $18 MILLION TO $20 MILLION.COMPANY ON TRACK TO MEET FULL-YEAR 2019 KEVEYIS REVENUE GUIDANCE OF $18 TO $20 MILLION.QTRLY TOTAL REVENUE $6.1 MILLION VERSUS $4.3 MILLION.Q2 REVENUE VIEW $4.7 MILLION -- REFINITIV IBES DATA.STRONGBRIDGE BIOPHARMA - ENROLLMENT IN PHASE 3 LOGICS STUDY FOR RECORLEV PROGRESSING WITH TOP-LINE DATA ANTICIPATED AT END OF Q1 2020.  Full Article

Strongbridge Biopharma PLC Reports Q3 2018 Results
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Strongbridge Biopharma plc ::REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 NON-GAAP LOSS PER SHARE $0.47.Q3 GAAP LOSS PER SHARE $0.44.Q3 EARNINGS PER SHARE VIEW $-0.39 -- THOMSON REUTERS I/B/E/S.Q3 REVENUE $5.3 MILLION VERSUS I/B/E/S VIEW $5.5 MILLION.KEVEYIS 2018 REVENUE GUIDANCE REVISED TO $16 MILLION - $17 MILLION.TO UTILIZE PORTION OF PROCEEDS FROM NOVO NORDISK DEAL TO REPAY OUTSTANDING DEBT OF $88 MILLION.STRONGBRIDGE - WILL AMEND CLINICAL TRIAL PROTOCOL FOR ONGOING PHASE 3 LOGICS STUDY TO EXPAND RANDOMIZED-PATIENT TARGET FROM 35 TO 54 PATIENTS.TOP-LINE RESULTS FROM EXPANDED LOGICS STUDY ARE EXPECTED IN Q4 OF 2019..PLANS TO CONDUCT A TYPE C MEETING WITH FDA IN Q1 OF 2019 TO DISCUSS PATH FORWARD FOR NDA FILING FOR RECORLEV.  Full Article

Strongbridge Biopharma PLC Enters Into Agreement For Novo Nordisk To Acquire The U.S. And Canadian Rights To Macrilen
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Strongbridge Biopharma plc ::STRONGBRIDGE BIOPHARMA PLC ENTERS INTO AGREEMENT FOR NOVO NORDISK TO ACQUIRE THE U.S. AND CANADIAN RIGHTS TO MACRILEN™ (MACIMORELIN).STRONGBRIDGE BIOPHARMA PLC - PURCHASE PRICE OF $7.00 PER SHARE.STRONGBRIDGE BIOPHARMA PLC - NOVO NORDISK TO PURCHASE APPROXIMATELY 5.2 MILLION ORDINARY SHARES OF STRONGBRIDGE BIOPHARMA PLC AT PURCHASE PRICE OF $7.00 PER SHARE.STRONGBRIDGE BIOPHARMA PLC - STRONGBRIDGE WILL RECEIVE AN UPFRONT PAYMENT OF $145 MILLION FROM NOVO NORDISK FOR U.S. AND CANADIAN RIGHTS TO MACRILEN.STRONGBRIDGE BIOPHARMA PLC - STRONGBRIDGE WILL RECEIVE TIERED ROYALTIES RELATED TO SALES OF MACRILEN THROUGH 2027.STRONGBRIDGE BIOPHARMA PLC - NOVO NORDISK TO FUND STRONGBRIDGE'S RARE ENDOCRINE COMMERCIAL FIELD ORGANIZATION FOR MACRILEN FOR UP TO THREE YEARS.STRONGBRIDGE BIOPHARMA PLC - TRANSACTION WILL RESULT IN GROSS PROCEEDS OF $36.7 MILLION.STRONGBRIDGE BIOPHARMA - CO'S CURRENT MACRILEN FIELD ORGANIZATION TO CONTINUE TO PROMOTE PRODUCT IN U.S. UNDER A 3-YEAR AGREEMENT WITH NOVO.  Full Article

Strongbridge Biopharma Plc Files For Resale Of Up To 26.5 Mln Ordinary Shares By The Selling Shareholders
Monday, 12 Mar 2018 

March 12 (Reuters) - Strongbridge Biopharma Plc ::STRONGBRIDGE BIOPHARMA PLC FILES FOR RESALE OF UP TO 26.5 MILLION ORDINARY SHARES BY THE SELLING SHAREHOLDERS - SEC FILING.  Full Article

Strongbridge Biopharma Reports Q4 GAAP Loss Per Share $0.47
Monday, 12 Mar 2018 

March 12 (Reuters) - Strongbridge Biopharma Plc ::REPORTS FULL-YEAR 2017 FINANCIAL RESULTS.Q4 NON-GAAP LOSS PER SHARE $0.31.Q4 GAAP LOSS PER SHARE $0.47.Q4 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE $16 MILLION TO $19 MILLION.‍ MACRILEN PRODUCT LAUNCH ON TRACK FOR MID-2018​.QTRLY ‍NET REVENUES OF $3.0 MILLION​.  Full Article

Strongbridge Gets Letters From Offices Of U.S. Senators Requesting Information On Marketing & Sales Of Keveyis
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Strongbridge Biopharma Plc ::STRONGBRIDGE BIOPHARMA - ON DEC 19, RECEIVED LETTERS FROM OFFICES OF U.S. SENATORS THAT REQUEST INFORMATION RELATING TO MARKETING & SALES OF KEVEYIS.STRONGBRIDGE BIOPHARMA - LETTERS REQUEST INFORMATION PRINCIPALLY RELATING TO THE PRICING OF KEVEYIS, AMONG OTHER THINGS - SEC FILING.STRONGBRIDGE BIOPHARMA - CO IN THE PROCESS OF RESPONDING TO THE LETTERS.  Full Article

Strongbridge Biopharma Q3 loss per share $0.98
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Strongbridge Biopharma Plc :Strongbridge Biopharma Plc provides corporate update and reports third quarter 2017 financial results.Q3 non-GAAP loss per share $0.35.Q3 GAAP loss per share $0.98.Q3 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.Strongbridge Biopharma Plc- ‍Recorlev (levoketoconazole) phase 3 top-line results remain on track with SONICS in Q2 2018 and LOGICS in Q4 2018​.Strongbridge Biopharma Plc- existing cash resources at Sept 30, net proceeds from Oct offering provides sufficient cash under current operating plan​.Strongbridge Biopharma Plc- ‍had pro forma cash and cash equivalents of $67.8 million as of September 30, 2017​.Strongbridge Biopharma Plc - qtrly total revenues $‍2.5 million​.  Full Article

Strongbridge Biopharma Plc announces proposed public offering of ordinary shares
Tuesday, 3 Oct 2017 

Oct 3 (Reuters) - Strongbridge Biopharma Plc :Strongbridge Biopharma Plc announces proposed public offering of ordinary shares.Strongbridge Biopharma Plc - ‍intends to offer and sell its ordinary shares in an underwritten public offering​.Strongbridge - to use proceeds for investment in expanded commercial infrastructure for KEVEYIS, continued development of RECORLEV and veldoreotide.  Full Article

Armistice Capital Llc reports 5.1 percent passive stake in Strongbridge Biopharma
Friday, 22 Sep 2017 

Sept 22 (Reuters) - Strongbridge Biopharma Plc :Armistice Capital Llc reports 5.1 percent passive stake in Strongbridge Biopharma Plc as of Sept 12, 2017 - SEC filing.  Full Article